nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—Erythema multiforme—Azathioprine—systemic scleroderma	0.00422	0.00422	CcSEcCtD
Ethosuximide—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.00418	0.00418	CcSEcCtD
Ethosuximide—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00417	0.00417	CcSEcCtD
Ethosuximide—Urinary tract disorder—Leflunomide—systemic scleroderma	0.00416	0.00416	CcSEcCtD
Ethosuximide—Connective tissue disorder—Leflunomide—systemic scleroderma	0.00414	0.00414	CcSEcCtD
Ethosuximide—Urethral disorder—Leflunomide—systemic scleroderma	0.00413	0.00413	CcSEcCtD
Ethosuximide—Weight decreased—Lisinopril—systemic scleroderma	0.0041	0.0041	CcSEcCtD
Ethosuximide—Immune system disorder—Azathioprine—systemic scleroderma	0.00403	0.00403	CcSEcCtD
Ethosuximide—Mediastinal disorder—Azathioprine—systemic scleroderma	0.00402	0.00402	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.004	0.004	CcSEcCtD
Ethosuximide—Erythema multiforme—Leflunomide—systemic scleroderma	0.00399	0.00399	CcSEcCtD
Ethosuximide—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00397	0.00397	CcSEcCtD
Ethosuximide—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00395	0.00395	CcSEcCtD
Ethosuximide—Anorexia—Mometasone—systemic scleroderma	0.00395	0.00395	CcSEcCtD
Ethosuximide—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.00394	0.00394	CcSEcCtD
Ethosuximide—Eye disorder—Leflunomide—systemic scleroderma	0.00394	0.00394	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00392	0.00392	CcSEcCtD
Ethosuximide—Haematuria—Lisinopril—systemic scleroderma	0.00385	0.00385	CcSEcCtD
Ethosuximide—Urticaria—Pentoxifylline—systemic scleroderma	0.00381	0.00381	CcSEcCtD
Ethosuximide—Immune system disorder—Leflunomide—systemic scleroderma	0.00381	0.00381	CcSEcCtD
Ethosuximide—Mediastinal disorder—Leflunomide—systemic scleroderma	0.0038	0.0038	CcSEcCtD
Ethosuximide—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00379	0.00379	CcSEcCtD
Ethosuximide—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00377	0.00377	CcSEcCtD
Ethosuximide—Agranulocytosis—Lisinopril—systemic scleroderma	0.00377	0.00377	CcSEcCtD
Ethosuximide—Eye disorder—Mycophenolic acid—systemic scleroderma	0.00376	0.00376	CcSEcCtD
Ethosuximide—Hyperkinesia—Prednisone—systemic scleroderma	0.00374	0.00374	CcSEcCtD
Ethosuximide—Mental disorder—Leflunomide—systemic scleroderma	0.00369	0.00369	CcSEcCtD
Ethosuximide—Euphoric mood—Prednisone—systemic scleroderma	0.00368	0.00368	CcSEcCtD
Ethosuximide—Malnutrition—Leflunomide—systemic scleroderma	0.00367	0.00367	CcSEcCtD
Ethosuximide—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.00363	0.00363	CcSEcCtD
Ethosuximide—Decreased appetite—Mometasone—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Ethosuximide—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.00359	0.00359	CcSEcCtD
Ethosuximide—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00358	0.00358	CcSEcCtD
Ethosuximide—Fatigue—Mometasone—systemic scleroderma	0.00357	0.00357	CcSEcCtD
Ethosuximide—Urethral disorder—Lisinopril—systemic scleroderma	0.00355	0.00355	CcSEcCtD
Ethosuximide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00353	0.00353	CcSEcCtD
Ethosuximide—Muscle spasms—Leflunomide—systemic scleroderma	0.00353	0.00353	CcSEcCtD
Ethosuximide—Mental disorder—Mycophenolic acid—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Ethosuximide—Malnutrition—Mycophenolic acid—systemic scleroderma	0.0035	0.0035	CcSEcCtD
Ethosuximide—Leukopenia—Azathioprine—systemic scleroderma	0.00348	0.00348	CcSEcCtD
Ethosuximide—Anorexia—Captopril—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Ethosuximide—Asthenia—Pentoxifylline—systemic scleroderma	0.00344	0.00344	CcSEcCtD
Ethosuximide—Erythema multiforme—Lisinopril—systemic scleroderma	0.00343	0.00343	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00338	0.00338	CcSEcCtD
Ethosuximide—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Ethosuximide—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Ethosuximide—Aplastic anaemia—Methotrexate—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Ethosuximide—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Ethosuximide—Leukopenia—Leflunomide—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Ethosuximide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00328	0.00328	CcSEcCtD
Ethosuximide—Abdominal pain—Mometasone—systemic scleroderma	0.00327	0.00327	CcSEcCtD
Ethosuximide—Mediastinal disorder—Lisinopril—systemic scleroderma	0.00327	0.00327	CcSEcCtD
Ethosuximide—Somnolence—Captopril—systemic scleroderma	0.00323	0.00323	CcSEcCtD
Ethosuximide—Agitation—Mycophenolic acid—systemic scleroderma	0.00322	0.00322	CcSEcCtD
Ethosuximide—Mental disorder—Lisinopril—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Ethosuximide—Lethargy—Prednisone—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Ethosuximide—Dizziness—Pentoxifylline—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Ethosuximide—Decreased appetite—Captopril—systemic scleroderma	0.00316	0.00316	CcSEcCtD
Ethosuximide—Malnutrition—Lisinopril—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Ethosuximide—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00314	0.00314	CcSEcCtD
Ethosuximide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Ethosuximide—Fatigue—Captopril—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Ethosuximide—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Ethosuximide—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00311	0.00311	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Ethosuximide—Skin disorder—Azathioprine—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Ethosuximide—Vomiting—Pentoxifylline—systemic scleroderma	0.00305	0.00305	CcSEcCtD
Ethosuximide—Psychotic disorder—Prednisone—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Ethosuximide—Muscle spasms—Lisinopril—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Ethosuximide—Rash—Pentoxifylline—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Ethosuximide—Dermatitis—Pentoxifylline—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Ethosuximide—Headache—Pentoxifylline—systemic scleroderma	0.00301	0.00301	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Captopril—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Ethosuximide—Asthenia—Mometasone—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Ethosuximide—Irritability—Prednisone—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Ethosuximide—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Ethosuximide—Nervous system disorder—Leflunomide—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Ethosuximide—Skin disorder—Leflunomide—systemic scleroderma	0.00291	0.00291	CcSEcCtD
Ethosuximide—Abdominal pain—Captopril—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Ethosuximide—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Ethosuximide—Anorexia—Leflunomide—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Ethosuximide—Nausea—Pentoxifylline—systemic scleroderma	0.00285	0.00285	CcSEcCtD
Ethosuximide—Diarrhoea—Mometasone—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Ethosuximide—Leukopenia—Lisinopril—systemic scleroderma	0.00282	0.00282	CcSEcCtD
Ethosuximide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.0028	0.0028	CcSEcCtD
Ethosuximide—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00278	0.00278	CcSEcCtD
Ethosuximide—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00278	0.00278	CcSEcCtD
Ethosuximide—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00276	0.00276	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00274	0.00274	CcSEcCtD
Ethosuximide—Anorexia—Mycophenolic acid—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00267	0.00267	CcSEcCtD
Ethosuximide—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Ethosuximide—Lethargy—Methotrexate—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Ethosuximide—Vomiting—Mometasone—systemic scleroderma	0.00263	0.00263	CcSEcCtD
Ethosuximide—Rash—Mometasone—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Ethosuximide—Asthenia—Captopril—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Ethosuximide—Dermatitis—Mometasone—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Ethosuximide—Decreased appetite—Leflunomide—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00259	0.00259	CcSEcCtD
Ethosuximide—Headache—Mometasone—systemic scleroderma	0.00259	0.00259	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00259	0.00259	CcSEcCtD
Ethosuximide—Fatigue—Leflunomide—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Ethosuximide—Somnolence—Mycophenolic acid—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Ethosuximide—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Ethosuximide—Abdominal pain—Azathioprine—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Ethosuximide—Skin disorder—Lisinopril—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Ethosuximide—Diarrhoea—Captopril—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Ethosuximide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Ethosuximide—Irritability—Methotrexate—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Ethosuximide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00247	0.00247	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00247	0.00247	CcSEcCtD
Ethosuximide—Fatigue—Mycophenolic acid—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Ethosuximide—Nausea—Mometasone—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Ethosuximide—Anorexia—Lisinopril—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Ethosuximide—Ataxia—Methotrexate—systemic scleroderma	0.00244	0.00244	CcSEcCtD
Ethosuximide—Weight decreased—Prednisone—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Ethosuximide—Dizziness—Captopril—systemic scleroderma	0.0024	0.0024	CcSEcCtD
Ethosuximide—Urticaria—Leflunomide—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Ethosuximide—Abdominal pain—Leflunomide—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Ethosuximide—Breast disorder—Methotrexate—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Ethosuximide—Hypersensitivity—Azathioprine—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Ethosuximide—Vomiting—Captopril—systemic scleroderma	0.00231	0.00231	CcSEcCtD
Ethosuximide—Rash—Captopril—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Ethosuximide—Dermatitis—Captopril—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Ethosuximide—Somnolence—Lisinopril—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Ethosuximide—Headache—Captopril—systemic scleroderma	0.00228	0.00228	CcSEcCtD
Ethosuximide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00226	0.00226	CcSEcCtD
Ethosuximide—Decreased appetite—Lisinopril—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Ethosuximide—Eosinophilia—Methotrexate—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Ethosuximide—Fatigue—Lisinopril—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Ethosuximide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Ethosuximide—Hypersensitivity—Leflunomide—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Ethosuximide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Ethosuximide—Diarrhoea—Azathioprine—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Ethosuximide—Nausea—Captopril—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Ethosuximide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Ethosuximide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Ethosuximide—Asthenia—Leflunomide—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Ethosuximide—Pancytopenia—Methotrexate—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Ethosuximide—Connective tissue disorder—Prednisone—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Ethosuximide—Dizziness—Azathioprine—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Ethosuximide—Asthenia—Mycophenolic acid—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Ethosuximide—Diarrhoea—Leflunomide—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Ethosuximide—Urticaria—Lisinopril—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Ethosuximide—Abdominal pain—Lisinopril—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Ethosuximide—Vomiting—Azathioprine—systemic scleroderma	0.00202	0.00202	CcSEcCtD
Ethosuximide—Eye disorder—Prednisone—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Ethosuximide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Ethosuximide—Drowsiness—Methotrexate—systemic scleroderma	0.002	0.002	CcSEcCtD
Ethosuximide—Rash—Azathioprine—systemic scleroderma	0.002	0.002	CcSEcCtD
Ethosuximide—Dermatitis—Azathioprine—systemic scleroderma	0.002	0.002	CcSEcCtD
Ethosuximide—Headache—Azathioprine—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Ethosuximide—Dizziness—Leflunomide—systemic scleroderma	0.00198	0.00198	CcSEcCtD
Ethosuximide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Ethosuximide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Ethosuximide—Immune system disorder—Prednisone—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Ethosuximide—Haematuria—Methotrexate—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Ethosuximide—Vomiting—Leflunomide—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Ethosuximide—Hypersensitivity—Lisinopril—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Ethosuximide—Dizziness—Mycophenolic acid—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Ethosuximide—Rash—Leflunomide—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Ethosuximide—Dermatitis—Leflunomide—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Ethosuximide—Mental disorder—Prednisone—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Ethosuximide—Nausea—Azathioprine—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Ethosuximide—Headache—Leflunomide—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Ethosuximide—Malnutrition—Prednisone—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Ethosuximide—Agranulocytosis—Methotrexate—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Ethosuximide—Asthenia—Lisinopril—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Ethosuximide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Ethosuximide—Rash—Mycophenolic acid—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Ethosuximide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Ethosuximide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Ethosuximide—Headache—Mycophenolic acid—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Ethosuximide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Ethosuximide—Nausea—Leflunomide—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Ethosuximide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Ethosuximide—Urethral disorder—Methotrexate—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Ethosuximide—Diarrhoea—Lisinopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Ethosuximide—Agitation—Prednisone—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Ethosuximide—Dizziness—Lisinopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Ethosuximide—Erythema multiforme—Methotrexate—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Ethosuximide—Nausea—Mycophenolic acid—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Ethosuximide—Eye disorder—Methotrexate—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Ethosuximide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Ethosuximide—Vomiting—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Ethosuximide—Immune system disorder—Methotrexate—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ethosuximide—Rash—Lisinopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ethosuximide—Dermatitis—Lisinopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ethosuximide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ethosuximide—Headache—Lisinopril—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Ethosuximide—Mental disorder—Methotrexate—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Ethosuximide—Malnutrition—Methotrexate—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Ethosuximide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Ethosuximide—Nausea—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Ethosuximide—Nervous system disorder—Prednisone—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Ethosuximide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Ethosuximide—Skin disorder—Prednisone—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Ethosuximide—Anorexia—Prednisone—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Ethosuximide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Ethosuximide—Rash—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Ethosuximide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Ethosuximide—Headache—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Ethosuximide—Leukopenia—Methotrexate—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Ethosuximide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Ethosuximide—Decreased appetite—Prednisone—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Ethosuximide—Fatigue—Prednisone—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Ethosuximide—Nervous system disorder—Methotrexate—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Ethosuximide—Skin disorder—Methotrexate—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Ethosuximide—Anorexia—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Ethosuximide—Urticaria—Prednisone—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Ethosuximide—Abdominal pain—Prednisone—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Ethosuximide—Somnolence—Methotrexate—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Ethosuximide—Hypersensitivity—Prednisone—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Ethosuximide—Decreased appetite—Methotrexate—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Ethosuximide—Fatigue—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Ethosuximide—Asthenia—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Ethosuximide—Diarrhoea—Prednisone—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Ethosuximide—Urticaria—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Ethosuximide—Dizziness—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Ethosuximide—Abdominal pain—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Ethosuximide—Vomiting—Prednisone—systemic scleroderma	0.000972	0.000972	CcSEcCtD
Ethosuximide—Rash—Prednisone—systemic scleroderma	0.000964	0.000964	CcSEcCtD
Ethosuximide—Dermatitis—Prednisone—systemic scleroderma	0.000963	0.000963	CcSEcCtD
Ethosuximide—Headache—Prednisone—systemic scleroderma	0.000958	0.000958	CcSEcCtD
Ethosuximide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000941	0.000941	CcSEcCtD
Ethosuximide—Asthenia—Methotrexate—systemic scleroderma	0.000917	0.000917	CcSEcCtD
Ethosuximide—Nausea—Prednisone—systemic scleroderma	0.000908	0.000908	CcSEcCtD
Ethosuximide—Diarrhoea—Methotrexate—systemic scleroderma	0.000874	0.000874	CcSEcCtD
Ethosuximide—Dizziness—Methotrexate—systemic scleroderma	0.000845	0.000845	CcSEcCtD
Ethosuximide—Vomiting—Methotrexate—systemic scleroderma	0.000812	0.000812	CcSEcCtD
Ethosuximide—Rash—Methotrexate—systemic scleroderma	0.000806	0.000806	CcSEcCtD
Ethosuximide—Dermatitis—Methotrexate—systemic scleroderma	0.000805	0.000805	CcSEcCtD
Ethosuximide—Headache—Methotrexate—systemic scleroderma	0.000801	0.000801	CcSEcCtD
Ethosuximide—Nausea—Methotrexate—systemic scleroderma	0.000759	0.000759	CcSEcCtD
